Somatropin (recombinant human GH)

Published · Researched 2026-09-21

Reference entry. Somatropin is not a secretagogue — it is direct replacement recombinant human growth hormone. It is included as the benchmark every peptide in this track is implicitly compared against ("peptides vs HGH").

Overview

Somatropin is 191-amino-acid recombinant human growth hormone (22 kDa), identical in sequence to endogenous pituitary GH. Major brands: Genotropin (Pfizer), Norditropin (Novo Nordisk), Humatrope (Eli Lilly), Omnitrope (Sandoz biosimilar), Saizen (Merck KGaA/EMD Serono), Zomacton. Approved indications include pediatric GH deficiency, adult GH deficiency, Turner syndrome, chronic kidney disease growth failure, SGA, and others depending on label. It is the only item in this track that delivers GH directly rather than stimulating endogenous release.

Social standing

  • Instagram: the "peptides vs HGH" debate is a recurring frame. HGH is consistently positioned as stronger and more direct, but costlier, with more pronounced side effects and significant counterfeit risk. 8 HGH-related entries in the extraction set.
  • Facebook Groups: HGH appears in comparison threads as the expensive reference — community cost debates cite synthetic HGH programs at roughly $1,000–3,000/month (ReadyRX-cited figure surfaced in the sermorelin research).
  • Threads: HGH-vs-peptides framing present in stack discussions.
  • Main praise (community framing): direct, predictable GH/IGF-1 elevation; no reliance on pituitary responsiveness.
  • Main complaints: cost, injection burden (daily), fluid retention/joint pain, insulin-resistance risk, suppression of endogenous pulsatility, counterfeit/underdosed black-market product, legal exposure.

Social validation — Tier 2

Strong evidence on Instagram (debate framing, comparison content) and Facebook Groups (cost/comparison threads); Threads coverage present but thinner; no dedicated owner-testimonial layer extracted in this round. Flagged Tier 2 — adequate for a reference entry whose facts are primarily regulatory/pharma rather than community-sourced.

Source What it proves
Instagram comparison/debate content (2025–2026) Proves HGH is the community's reference standard and cost/side-effect anchor
Facebook Group cost threads Proves the ~$1,000–3,000/mo community cost framing for pharma HGH
Gray-market price list (i.looksmax.org, "PEPTIDE PRICE LIST 2026") Proves black-market HGH pricing exists as a distinct tier (24 IU $140; 36 IU $210 — single source)

Key specs table

Property Value
Class Recombinant human growth hormone (somatropin), 191 aa, ~22,125 Da
CAS 12629-01-5
Mechanism Direct GH replacement — binds GH receptor; raises IGF-1; suppresses endogenous pulsatile GH via negative feedback (unlike secretagogues)
Half-life Short (SC ~3–4 h typical; exact label figure not re-verified — UNVERIFIED)
Route Subcutaneous injection (daily); long-acting weekly formulations exist (e.g., somatrogon, lonapegsomatropin — separate products)
Labeled dosing Indication- and weight-based (pediatric and adult GHD regimens differ); exact current labels not re-read — UNVERIFIED detail
FDA/EMA status Approved prescription drug (multiple brands, biosimilars)

Pricing

  • MSRP / cash price: US cash pricing for branded somatropin is indication- and dose-dependent; community-cited range ~$1,000–3,000/month (ReadyRX-cited figure via sermorelin research; single secondary source — UNVERIFIED). Insurance coverage applies only to labeled indications.
  • Gray/black-market street: single 2026 gray-market price list (i.looksmax.org): HGH 24 IU $140; 36 IU $210 — single source, UNVERIFIED, counterfeit risk widely discussed.
  • Facebook Marketplace range: no listings observed 2026-09-20.

What's included / what's needed

Pharma: prefilled pens/cartridges (e.g., Genotropin pen, Norditropin FlexPro), lyophilized vials with diluent, needles; pharmacy dispensing with cold-chain. Black-market: vials of varying provenance — counterfeit risk is a standing community warning.

Support reality

Full pharma support: manufacturer patient programs (e.g., Pfizer/Novo Nordisk support services), pharmacy counseling, endocrinologist supervision for labeled use. Black-market channel has none — this is the core community risk differentiator vs peptides.

Regulatory & safety status

FDA/EMA-approved prescription drug for labeled indications; prescription-only; not approved for anti-aging, bodybuilding, or general wellness use. WADA-prohibited at all times (S2). Label safety signals: fluid retention/edema, carpal-tunnel symptoms, joint/muscle pain, insulin resistance and hyperglycemia (diabetes risk), intracranial hypertension (rare), injection-site reactions; contraindicated in active malignancy and acute critical illness (standard GH warnings — exact current label not re-read today, treat as UNVERIFIED detail). Suppresses endogenous GH pulsatility with chronic use.

Community verdict

Somatropin is the yardstick, not the contender: everything in this track is measured against direct GH, and the community's verdict is consistent — HGH works more directly but costs an order of magnitude more, carries heavier metabolic and legal baggage, and the black-market supply is a counterfeit minefield. That cost/risk gap is precisely the market window the secretagogues occupy.

Image log

  • hero: present — somatropin-rhgh-hero.jpg (observation 2026-09-20)
  • side: present — somatropin-rhgh-side.jpg
  • detail: present — somatropin-rhgh-detail.jpg
  • box: present — somatropin-rhgh-box.jpg
  • rear: MISSING — no distinct rear-view image located
  • top: MISSING — no distinct top-view image located
  • inuse: MISSING — no real owner in-use photo located
  • scale: MISSING — no scale-reference photo located

All images: curl HEAD/GET-checked, magic-verified, JPEG, observation 2026-09-20. Zero AI-generated.

Open questions / UNVERIFIED

  • Exact current US cash prices by brand/dose (only secondary ranges collected).
  • Exact label half-life and dosing figures (labels not re-read).
  • Black-market price/quality data beyond a single 2026 price list.
  • Long-acting GH formulations (somatrogon etc.) were out of scope for this track.

Not medical advice. This file is research documentation only; nothing here is a recommendation to use any compound.

Somatropin (recombinant human GH) — box view
box view Original vendor page URL not recorded in research dossier
Somatropin (recombinant human GH) — detail view
detail view Original vendor page URL not recorded in research dossier
Somatropin (recombinant human GH) — hero view
hero view Original vendor page URL not recorded in research dossier
Somatropin (recombinant human GH) — side view
side view Original vendor page URL not recorded in research dossier

Named sources

  • Instagram — the "peptides vs HGH" debate is a recurring frame.
  • Facebook Groups — HGH appears in comparison threads as the expensive reference — community cost debates cite synthetic HGH programs at roughly $1,000–3,000/month (ReadyRX-cited figure surfaced in the sermorelin research).
  • Threads — HGH-vs-peptides framing present in stack discussions.
  • Instagram comparison/debate content (2025–2026) — Proves HGH is the community's reference standard and cost/side-effect anchor (2025–2026)
  • Facebook Group cost threads — Proves the ~$1,000–3,000/mo community cost framing for pharma HGH
  • Gray-market price list (i.looksmax.org, "PEPTIDE PRICE LIST 2026") — Proves black-market HGH pricing exists as a distinct tier (24 IU $140; 36 IU $210 — single source) (2026)
  • ReadyRX — - **Facebook Groups:** HGH appears in comparison threads as the expensive reference — community cost debates cite synthetic HGH programs at roughly $1,000–3,000/month…

Source URLs were not recorded for these references.